News Hub | News Direct

Lifestyle

Beverage: Coffee/Tea/Non-Alcoholic Beverage: Spirits/Beer/Wine Casino/Gaming Fashion Food/Cooking/Baking Health & Fitness Home Goods Hospitality Leisure Activities & Hobbies Parenting Pets Photography Seniors Travel & Tourism
Article thumbnail News Release

Kim Sledge of Sister Sledge, the recording artists behind the international hit song “We are Family” Urges Support for The American Center for Cures

The American Center for Cures

Kim Sledge of Grammy Award winning vocal group Sister Sledge, famed for its international hit song and platinum album, “We are Family,” advocated her support for The American Center for Cures (ACC), an audacious “moonshot” mission to prevent, treat or cure diseases that plague every American family, with a new song titled, “ Unity Strong.” Ms. Sledge also shared personal commentary in support of the ACC: “I’m Kim Sledge from the recording group Sister Sledge. We recorded the international hit song, ‘We Are Family.’ I write today in support of The American Center for Cures. Having had the privilege of traveling around the world and looking in the eyes of people of all colors, ages, and cultures, and having seen both healthy, as well as, unfortunately disease affected communities, I am in full support of an initiative I was introduced to by a very dear friend of our families, Mr. Lou Weisbach, CEO and Co-Founder of ACC. Lou, Ruthie, and their family have, over the years, shared in and supported some of my family’s great times and losses. To think that some of those sad times could have been avoided, but even more to know, now there’s a new hope, and soon other families won’t have to go through the despair of disease and loss. I am truly grateful and ecstatic to hear of the possibilities The American Center For Cures has planned. Its mission is awe inspiring and I believe it is divinely designated for such a time as this. Globally, we are in dire and imminent need of a fully funded mission to prevent, treat and cure the diseases that plague every American family. Today, I cry out for unity regarding the efforts of the ACC which can bring healing wholeness and perhaps a bond of peace. We are all diverse families sharing this small planet and we all want the same thing: healthy longevity. The ACC is unequivocally the right solution to confront the nation’s health crisis and the plan is already in place. Right now, we need only to act on it by uniting our hearts, hope, and hands in active support with quick fire momentum to result in an epic unified outcome. Let’s put these disease groups out of business. Too many families have been desperate for far too long. It’s time for prevention, cures, healing, and wholeness. Lou and Dr. Boxer have taken the position of warriors for this cause. In unity, let’s put our hands to the plow with them and burst open the doors for The American Center for Cures. I’ve often heard it said, ‘how good and pleasant it is for brothers to dwell together in unity.’ I see only one other place where we as families strive with greater unity, and that place is in love. We can do this, together. We are family. We are unity strong.” The ACC initiative was introduced by co-founders Lou Weisbach and Dr. Rick Boxer, who was recently appointed by President Joseph Biden to the National Cancer Advisory Board. Their tireless, exemplary, and passionate efforts will enable us to turn theory into practice and finally make the families of our nation and the world recipients of long-awaited prevention, treatments, and cures through fully funded mission-based entities in the private sector individually focused on major diseases with CEO’s that are accountable and responsible to finally get the job done. Former Secretary of Health Tom Price commented that, “when this plan is approved it will rival the greatest achievements in US history and offer the sense of urgency that all American families yearn for and deserve when battling disease.” Ms. Sledge, who is also an ordained minister, and the ACC CEO Lou Weisbach are available for interviews to personally discuss this bipartisan initiative and its mission to unite medicine, science, pharmaceuticals, business, and government to seek out new treatments and cures for Alzheimer’s, diabetes, Parkinson’s, mental diseases, many forms of cancer, and several others. You can listen to “Unity Strong,” Ms. Sledge’s new song dedicated to mission of the ACC, here. About American Center for Cures The American Center for Cures (ACC) initiative is a bipartisan mission to prevent, treat and cure diseases that plague every American family. The initiative will be funded by the sale of $750B bonds by the Federal Reserve, providing the capital needed to accelerate the current trajectory of medicine. Annual interest will be paid through the licensing of new compounds and drugs to pharmaceutical companies. The principal will be repaid by savings provided to the United States Government through successes in the areas of prevention and cures. The ACC business model will cost the government and taxpayers nothing, making this the single most impactful investment on behalf of the American people in the nation’s history. For more information, please visit https://theamericancenterforcures.org. Contact Details Jenna Beaucage +1 508-340-6851 jbeaucage@rainierco.com Company Website https://theamericancenterforcures.org

March 23, 2023 08:15 AM Eastern Daylight Time

Article thumbnail News Release

CleverTap Gaming Unveiled at GDC 2023

CleverTap

CleverTap, the all-in-one customer engagement platform, today at Game Developers Conference 2023 unveiled CleverTap Gaming – soon to go live in the summer of 2023. Through full player management, the latest offering will help boost revenue from LiveOps, Lifecycle Marketing, and Remote Configuration by 3x with personalization across the entire player journey. The platform is powered by TesseractDB™, CleverTap's proprietary data engine, which is built for real time triggering & segmentation with high performance, low latency, and massive economies of scale. CleverTap Gaming brings holistic and sophisticated multi-channel campaigns inside and outside the in-game experience. With a simplified UI, it reduces the dependence on technical teams and increases operational efficiency. By leveraging CleverTap’s proprietary TesseractDB™, it offers rich granularity with unlimited data points and no restrictions on lookback period. Previously, the lack of these features could have been a limiting factor for game studios trying to maximize retention and lifetime value, but CleverTap Gaming unlocks these use cases enabling game studios to scale their personalization efforts to new heights. Also, given its versatility, CleverTap Gaming offers a vast array of benefits within various functions in typical game studios: LiveOps: With over 2000 unique player attributes (10x more than the industry average), LiveOps Managers can improve the relevance of their offers with much more granular insights into user behavior and preferences. Marketing: Consumers have vastly different preferences and a single journey does not fit each and every one of them. As such, conditional logic, advanced branching, and unified composition flow across all channels can help marketers plan campaigns with contingencies in mind. The advanced segmentation feature can also help marketers create better-targeted campaigns from the outset. Development: The ability to integrate with existing backend solutions lowers the barrier to transition for gaming studios with other solutions. Native Unity SDK means the platform can enhance developer productivity and shorten release cycles considerably. “Modern gaming is evolving. They are no longer static endpoints – and with features like LiveOps and Remote Configuration, developers are empowered to make changes in real-time without the constraints of approvals and a relaunch.” said Lawrence Hsieh, Principal Product Manager at MobilityWare. “CleverTap Gaming gives us an all-in-one cost-effective solution that ensures consistency and efficiency while not only developing but also promoting an update.” “With over 2.6 billion mobile game players globally, it is only a matter of time before the growth trajectory flattens out and retention becomes a bigger area of focus. We hope that CleverTap Gaming can accompany those studios looking to stay ahead of the curve by maximizing their pre-existing user base via personalized and relevant messaging,” said Sunil Thomas, Co-founder and Executive Chairman at CleverTap. “When we acquired Leanplum last year, we looked to strengthen our footprint within various verticals and geographies. CleverTap Gaming is another step in this direction, and we are confident that it will further accelerate our growth journey.” About CleverTap Gaming, powered by Leanplum CleverTap Gaming is powered by Leanplum and helps gaming studios achieve engagement and revenue goals by providing the tools and expertise to deliver more personalized player experiences at scale. Learn more about what CleverTap can do for your brand at clevertap.com. For a platform demo, visit clevertap.com/live-product-demo/ About CleverTap CleverTap is the all-in-one customer engagement platform that helps brands personalize and optimize all consumer touch points to improve user engagement, retention, and lifetime value. It's the only solution built to address the needs of retention and growth teams, with audience analytics, deep-segmentation, multi-channel engagement, product recommendations, and automation in one unified product. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering both speed and economies of scale. CleverTap is trusted by 2000 customers, including Electronic Arts, TiltingPoint, Gamebasics, Big Fish, MobilityWare, TED, English Premier League, TD Bank, Carousell, AirAsia, Papa Johns, and Tesco. Backed by leading investors such as Sequoia India, Tiger Global, Accel, and CDPQ the company is headquartered in Mountain View, California, with presence in San Francisco, New York, São Paulo, Bogota, London, Amsterdam, Sofia, Dubai, Mumbai, Singapore, and Jakarta. For more information, visit clevertap.com or follow on LinkedIn and Twitter. Forward-Looking Statements Some of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release. Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction. Contact Details Sony Shetty sony@clevertap.com Company Website https://clevertap.com/

March 23, 2023 04:45 AM Eastern Daylight Time

Article thumbnail News Release

How Champagne Competes With The Stock Market

Vint

The story of Champagne includes Romans bringing vines to present day France, monks perfecting the carbonation process, and more recently, investment returns that outpace the most notable indices. In an ever more volatile stock market, alternative assets are becoming more popular. This includes fine wines such as Champagne. Impressive Returns Champagne has been the second best performing region over the past two years, gaining 56.0% (through February 2023) on the London International Vintners Exchange (Liv-ex) versus an S&P 500 return of around 4.4% through the same time frame. The names leading the way for this index include Dom Perignon, Bollinger, Krug and Cristal. To understand the factors behind Champagne’s rise, you have to look at its changing place within the secondary market. According to a Liv-ex report, Champagne only amounted to about 2% of secondary trading a decade ago. As of September of 2022, that share had climbed to 12.4%. This is demonstrated evidence that demand and liquidity continue to increase for bubbly. When taking these factors into account, Champagne has emerged as an increasingly compelling investment category. Scarcity is also a factor in younger vintages. The Champagne region of France has not had the most consistent of growing seasons, and not every year’s crop becomes a vintage. 2021 for instance had early frost, which damaged yields for many producers. While this was a major disappointment to wine lovers, it feeds into the supply and demand variables that drive wine prices on the secondary market. 2022 was also a banner year for the trade of Champagne on Liv-ex, with 2008 Cristal being the most traded wine by value. Hedging Risk Obviously it would be ill advised to think this asset will constantly outpace equities. The broader appeal of Champagne and other investment grade wines lies in its non-corollary nature. Wine markets largely operate independently from traditional equity and bond markets. That’s why diversification into this asset class could provide a strong hedge against volatility for portfolios. There is also a potential hedge for economic conditions outside of public market volatility. Champagne’s performance is led by high profile names such as Krug or Bollinger. Because of the high priced nature of these wines, there is a bit of a buffer against broad economic uncertainty. That’s not to say that wine markets won’t be hit by economic circumstances, but the pocketbooks of the consumer-base capable of paying for these levels of Champagne are a little more insulated. This means spending power for collecting and drinking these wines stands to be less impacted by an economic slowdown. If you reference the Liv-ex 1000 index performance through two periods of major economic disruption, 2008 and 2020, you’ll note that price movements for the 100 most sought after wines were either quicker to rally, or less impacted as a whole. Simplify this down to the Champagne 50 index alone, and performance has been even more steady. Through 2020 and the covid-19 pandemic, investment-grade Champagne prices were relatively unscathed relative to the stock market. As the prices of the most in-demand collectible fine wines have continued to appreciate over time, the relative value of top champagne bottlings has increased dramatically. Another important catalyst has been the successful positioning of champagne as more than just wine, but as a true luxury good - the fact that major players in fashion and luxury such as LVMH, also own some of the most prestigious champagne houses is no accident. Their marketing leverage is being used to great effect, as global demand, secondary market activity, and prices are following accordingly. Investing in Alternatives Like Wine Alternative investments under management are projected to reach $17.2 trillion by 2025, as investors seek diversified returns. Investment platform Vint views wine and spirits as a key piece of that mix, given the stability and historical performance of the market. Investing in the asset class through a professional can be more conducive to long term results, rather than simply storing a few wines in your basement. Vint’s platform allows investors to invest in shares of wine through securitized offerings, rather than having to go out and purchase an entire wine collection on your own. Vint makes decisions based on proprietary analysis and fundamental research, to attempt to bring the return potential of fine wine and rare spirits to investors. This article was originally published on Benzinga here. Founded in 2019, Vint set out to financialize fine wine and spirits and create a new asset class. Vint received SEC qualification in 2021, thereby creating the first fully-transparent, efficient platform for wine, spirits, and futures collection investing. Vint offers expert-curated, thematic collections of fine wine & spirits to institutional, accredited, and non-accredited investors. Since launching, Vint has securitized and offered over $6M worth of assets. Through Q3 2022, Vint has generated returns of 28.3% for asset exits on a net annualized basis since inception. Vint is backed by leading investors Montage Ventures, MS&AD Ventures, Goat Rodeo Capital, Fintech Ventures & Slow Ventures. To learn more about Vint, visit Vint.co. This is not investment advice. All investors should do their own research, due diligence, and make their own decisions when it comes to investing capital in markets. Please read Vint’s disclaimer Contact Details Brady Weller Brady@vint.co Company Website https://vint.co/

March 22, 2023 09:30 AM Eastern Daylight Time

Article thumbnail News Release

Detecting Early Signs of Heart Disease

YourUpdateTV

One in five people worldwide have inherited high lipoprotein(a) and most don’t know it. Because high Lp(a) isn’t screened for, often the first sign of this condition can be a heart attack or stroke. There are more than 60 million people in the United States at high risk for a heart attack or stroke because they were born with high lipoprotein(a). Recently, Katherine Wilemon, founder and CEO of the Family Heart Foundation, teamed up with preventive cardiologist Dr. Seth Baum, chief scientific officer of Flourish Research, on a nationwide satellite media tour to raise awareness and encourage people to get screened. A video accompanying this announcement is available at: https://youtu.be/NGQBZxqF-GI Lp(a) is a cholesterol-like substance that is unrelated to the food you eat or how you live. People inherit Lp(a) levels from their parents and high levels of Lp(a) significantly increase your likelihood of having a heart attack or stroke. High Lp(a) is a "triple threat" as it can clog your arteries like LDL cholesterol but it also promotes inflammation and increases the risk of your blood clotting. If you have heart disease or have had a stroke, or someone in your family has experienced cardiovascular disease, it is important to get screened for high Lp(a). In addition, if your LDL cholesterol is very high — over 190 mg/dL —you should also have your Lp(a) tested. Research from the Family Heart Foundation revealed that fewer than 1% of Americans had ever had their lipoprotein(a) tested – and it’s a simple blood test. “The truth is with 20% of the population affected, and heart disease continuing to be the single biggest threat to one’s ability to live a long healthy life, everyone should be screened,” said Dr. Baum. The Family Heart Foundation declared March 24 Lp(a) Awareness Day to raise awareness worldwide. In its second year, this day draws attention to high Lp(a) as an under-recognized cause of premature heart disease and stroke. “March 24 is a perfect time for everyone to think about their family history, be screened for high Lp(a) and maybe change the future for millions of Americans,” said Wilemon. For more information, visit FamilyHeart.org. The Family Heart Foundation’s Care Navigation team can answer questions and connect you to a healthcare provider near you. About Katherine Wilemon On the month she turned 39 years old, Katherine Wilemon’s world was rocked by a heart attack caused by a complete artery blockage. It was the importance of family that drove Katherine to investigate the deeper physiological issues that contributed to her cardiac event. She learned that she had familial hypercholesterolemia (FH), and, years later, that she also had elevated levels of lipoprotein(a). The more Katherine advocated for herself, the more she encountered an inadequate understanding of genetic conditions such as FH. Always an entrepreneur, she founded the Family Heart Foundation in 2011 to increase early diagnosis and treatment. Over the years the Foundation has helped create a national research registry for FH, established diagnostic codes and consensus statements for care, and provided a community for those living with inherited cholesterol disorders. Now, the organization has expanded to drive awareness and scientific understanding of Lp(a) so that others with high levels can better protect themselves and their families. About Seth Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC Dr. Seth J. Baum is Chief Scientific Officer at Flourish Research, and clinical affiliate professor of Cardiology at FAU Medical School. He actively consults in Clinical Lipidology and Cardiovascular Disease Prevention and continues to offer lipoprotein apheresis for patients in southeast and central Florida. Dr. Baum has practiced Preventive Cardiology and Clinical Lipidology since 2000. He is a fellow of the American College of Cardiology, the American Heart Association, the American College of Preventive Medicine, the National Lipid Association, and the American Society for Preventive Cardiology. Dr. Baum is a past President of the American Society for Preventive Cardiology (ASPC). He currently serves on both the ASPC and Family Heart Foundation Advisory Boards. He has published over 100 peer reviewed papers and abstracts as well as two books. In 2013, he was awarded Cleveland Heart Lab’s “Heart Award” for lifelong dedication to Preventive Medicine. In 2019, Dr. Baum received Mended Hearts’ biennial Dwight Emary Harken Award. Dr. Baum is the Founder of Excel Medical Clinical Trials, LLC, a consortium of clinicians dedicated to the safe and professional conduct of high-level scientific trials. He has served as Principal Investigator in over 100 clinical trials covering a broad range of disease states. Dr. Baum is the Chief Scientific Officer of Flourish Research, a leading national clinical research company. Dr. Baum is a graduate of Columbia College and Columbia College of Physicians and Surgeons, and completed training in Internal Medicine, Cardiology, Interventional Cardiology, and Electrophysiology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

March 22, 2023 09:19 AM Eastern Daylight Time

Video
Article thumbnail News Release

What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?

BioRestorative Therapies, Inc.

By Julian Richard, Benzinga Successful Autologous Cell-Based Therapies The global CAR-T cell therapy market is growing continuously due to novel clinical and commercial developments in this therapy. As a result, the Global CAR-T cell therapy market is expected to be worth USD 4.36 billion by 2028 from 2.31 billion in 2023, growing with a healthy CAGR of 13.5% during the forecast period. Companies like Pfizer (NYSE: PFE) Johnson & Johnson (NYSE: JNJ, Bristol-Meyers Squibb (NYSE: BMY) as well as Gilead Sciences (NASDAQ: GILD) all are focusing on this innovative CAR-T cell therapy. Autologous cell based therapies are personalized therapies using your own cells to target a disease or disorder. Personalized therapies targeting cancer such CAR-T cell therapies have generated impressive clinical results with complete remission rates in B-acute lymphoblastic leukemia in over >80% of patients. One of the reasons this therapy has been successful is because it is autologous. In 2017, the U.S. FDA approved the first two CAR-T cell therapies: Novartis’ Kymriah ® for treatment of acute lymphoblastic leukemia (ALL) and Gilead subsidiary Kite Pharma’s Yescarta ® for certain types of large B-cell lymphomas, a type of non-Hodgkin lymphoma. These autologous therapies are patient-specific where the therapeutic CAR-T cells are created from a patient’s own cells. The Value of Autologous Stem-Cell Therapies Autologous stem-cell therapy is a novel medical technology that is revolutionizing the way the medical community approaches the treatment of metabolic, autoimmune and degenerative diseases. Additionally, this technique has been used successfully to develop skin grafts for wound care, treat burns and bedsores and speed up recovery after surgery. The method involves extracting stem cells from a patient’s body and culturing them in laboratory conditions before reintroducing them into the patient. Stem cells are a unique type of cell that can develop into any other cell in the body. These “supercharged” cells can be used for tissue regeneration and repair, making stem cells a potent tool in modern personalized medicine. Stratified medicine simply cannot compete with this customization, precision, and safety profile. The main benefit of using autologous cells is that these cells come from your own body and therefore do not trigger any immunological rejection reactions. They also minimize the risk of infection from non-patient sources. This allows autologous cell therapy to be used safely over a longer term, ensuring that the patient can access consistent and reliable treatment without risk of rejection or complications due to incompatibility. In 2021, the autologous cell therapy market was valued at $4.3 billion and was projected to skyrocket to $29.1 billion by 2031—marking a compounded annual growth rate (CAGR) of 21% from 2022-2031. Although the market is still nascent, it is expected to eventually create a new healthcare sector with revenue similar to that of the pharmaceutical, biotechnological, and medical devices industries. An Autologous Stem Cell-Based Approach to treat Disc Pain BioRestorative Therapies Inc (NASDAQ: BRTX) focuses on innovative “home-grown” autologous stem-cell therapies to address unmet needs in patients with common yet serious diseases. It was founded by medical doctors, scientists and world-renowned stem-cell researchers committed to developing novel stem-cell therapies. The lead candidate in BioRestorative’s musculoskeletal stem-cell platform is BRTX-100, administered as a minimally-invasive single intradiscal injection. BRTX-100 is currently being evaluated in an FDA gold standard phase 2 double-blind, controlled, randomized study in those with chronic lumbar disc disease (cLDD). Chronic lumbar disc disease affects over 500 million individuals globally and is currently only treatable with opioids and surgery. Despite being the most commonly prescribed drug for cLLD, no clinical data supports the use of opioids in cLLD, which only serves to increase the opioid crisis in the USA. Surgery for cLLD carries many disadvantages and limitations. The cost of surgery can be high. While surgical intervention may reduce pain in some cases, it often fails to restore previous levels of function or mobility. Revision or reoperation rates for surgical intervention in the spine can be upwards of 20-30% of the cases performed. Furthermore, a more extended recovery period is associated with an increased risk of mechanical instability of the spine and potentially increased failure rates compared to non-surgical treatments. It would appear a bright future awaits BioRestorative Therapies and the autologous cell therapy market in general as patients increasingly look at personalized alternatives to surgery and conventional medicine. BRTX-100 is an innovative and minimally-invasive technology set to revolutionize lower back pain treatment. Visit https://www.biorestorative.com for more information on the company and its product candidates. This article was originally published on Benzinga here. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

March 22, 2023 09:15 AM Eastern Daylight Time

Article thumbnail News Release

Global Wellness Company Fine Hygienic Holding Launches eon Longevity, an All-Natural Herbal Longevity Supplement

Fine Hygienic Holding

Fine Hygienic Holding (FHH), one of the world’s leading wellness groups, today announced the launch of eon ™, a powdered, herbal beverage supplement that supports overall health and longevity. Comprising an all-natural, proprietary herbal blend, eon Longevity +Plus (eon’s signature product) underwent one of the largest clinical studies in the supplement space. The results verified that eon supports the health of the cardiovascular, respiratory, and gastrointestinal systems; regulates normal metabolic balance; and helps reduce inflammation — all of which result in a healthier and stronger body. One of the most impactful findings is eon’s ability to reduce inflammation, which is a breakthrough since inflammation is at the core of most, if not all, diseases in the human body. “With these outstanding clinical results, it can be argued that eon could be the healthiest beverage a person can consume and should be part of everyone’s personal wellness program to improve quality of life and even life expectancy,” said Medical Wellness Association (MWA) President Dr. Christopher Breuleux, who underwrote the clinical study. “We are a company devoted to improving people’s health and lives by providing reliable, tested, high-quality products,” said eon Founder and FHH President of Wellness Elia G. Nuqul. “We are extremely happy to finally make this amazing product available after more than 3.5 years of hard work. The biggest reward in all this is knowing we have something that can really improve people’s health and lives, and unlock their longevity at an affordable price.” eon is the first FHH product to be fully procured, manufactured, packaged and launched in the U.S. The beverage supplement has also been professionally certified by the MWA. FHH CEO James Michael Lafferty said, “eon reduces total body inflammation, resulting in significant health benefits. You will not find a modern drug using these powerful ingredients to battle inflammation, which is often linked to conditions such as cancer, heart disease, diabetes, asthma, and Alzheimer's disease.” Inspired by Tea from the Mediterranean The inspiration behind eon’s innovation came from a viral video viewed by Lafferty and Nuqul. It featured a centenarian man youthfully navigating his village, climbing trees, and attributing his long and healthy life to his herbal tea. Captivated by this video, Nuqul embarked on an international sojourn to locate the elder gentleman and learn directly about the drink that kept him so spry. After studying, modifying, and enhancing the tea with the MWA, eon is the result. “eon is a beautiful marriage of nature and science. The ingredients of this beverage supplement have been tested independently and proven to have significant health benefits, most notably in the battle of inflammation and the systemic problems it causes,” added Lafferty. “Here was this centenarian living a healthy and full life attributed to drinking this drink, so we asked ourselves: What if the root to longevity is in the Mediterranean — and what if this benefit was available to everyone for the same price as a cup of coffee?” Clinical Study Results The clinical study, underwritten by the Medical Wellness Association, was one of the largest ever in the wellness supplement industry. Each participant consumed the beverage daily, all under medical supervision. The clinical trials scientifically proved, with statistical significance, that the consumption of eon Longevity +Plus yielded a range of health benefits, including: Reduces and controls inflammation and pain, a breakthrough since inflammation is at the core of most, if not all, diseases in the human body Supports cardiovascular and respiratory health Powerful source of antioxidants Regulates normal metabolic syndrome and improves gastrointestinal (gut) health Improves kidney and liver function (*amongst a subset of the clinical study) Reduces pre-diabetes risk factors Reduces stress Improves mood, vitality and sleep eon Now Available In addition to the clinically proven eon Longevity +Plus (which includes the highly bioavailable curcumin), customers also have access to eon Longevity, which is the all-natural herbal proprietary blend inspired by the centenarian man (without the curcumin). For best results, consume either blend at least once daily mixed with warm or cold water on an empty stomach. It may also be added to other beverages such as coffee or tea. The beverage supplement is only available as individual stick packs online at www.eon-longevity.com. About eonThe eon Longevity Blends™ are all-natural, herbal beverage supplements inspired by a generations-old formula and created by nature. Through one of the largest clinical studies conducted in the supplement space, eon Longevity +Plus (eon’s signature product) has been scientifically proven to provide significant health benefits when consumed at least once a day, especially through the reduction of inflammation. eon is part of Fine Hygienic Holding, one of the world’s leading wellness groups. More at www.eon-longevity.com. About Fine Hygienic HoldingFine Hygienic Holding (FHH), one of the world’s leading wellness groups and MENA’s leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. Committed to becoming “the shining star of the Arab FMCG business world,” the Group focuses on wellness, sustainability, pioneering CSR programs, and state-of-the-art production processes. Fine Hygienic Holding offers a diverse array of award-winning products, including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls. It also offers away-from-home products to accommodate all types of private and public institutions in addition to its advanced range of personal protective equipment and long-lasting germ protection solutions. FHH also brings Nai natural iced teas and innovative nutritional supplements, such as eon and Motiva, to the market. Contact Details Rana Kawalit | │ Corporate Communication & PR Director +971 54 531 5575 Rkawalit@finehh.com Company Website https://www.finehh.com/

March 21, 2023 05:20 PM Eastern Daylight Time

Article thumbnail News Release

Traveling on a Budget in 2023

YourUpdateTV

While prices for flights, hotels and rental cars are all up across the board, demand for travel isn’t slowing. A recent survey from pay over time provider, Affirm, revealed that despite record-high costs, the average person plans to take three trips this year and spend over $3,000 on travel. Furthermore, 3 in 4 of Millennial and Gen-Z respondents plan to take up to 6 trips this year, with over half planning to spend up to $5,000 on travel. Traveling on a budget can help ensure that people are spending responsibly while also providing ways to make their money go further. Affirm SVP and Financial Health Expert, Katrina Holt, participated in a nationwide satellite media tour, offering her top tips for financially-conscious travelers in 2023: Don’t forget to set a budget. The recent Affirm survey found that nearly 1 in 5 plan to travel this year without setting a budget beforehand, which can easily lead to overspending. When creating a budget, be sure to consider expenses across accommodation, meals, transportation and shopping. Use a transparent, flexible pay over time option like Affirm to spread out your costs and stick to your budget. By selecting Affirm at checkout, approved travelers can split travel costs into biweekly or monthly payments. Travelers will see the total cost of their purchase and will never pay more than they agree to upfront Affirm does not charge late or hidden fees. Watch out for gimmicks that come with travel credit cards. Early sign up bonuses might be enticing, but can easily lead to overspending as you try to hit the minimum. 0% APR credit card promotions can come with deferred interest and surprise you with balloon payments down the line. A video accompanying this announcement is available at: https://youtu.be/2ZCQtGXL7y8 Affirm is helping travelers by offering a smarter way to pay at some of the largest travel merchants in the US and Canada, including American Airlines, Expedia, Hotels.com, KAYAK, Vrbo, Priceline, and more. For more information, visit Affirm.com About Katrina Holt Katrina Holt is the SVP, Operations and Financial Health Expert at Affirm. Affirm is a new kind of payment network — one based on trust, transparency and putting people first. As a technology and financial services executive, Katrina brings more than 27 years of financial services, operations, and risk management leadership. Prior to Affirm, she was the Chief Compliance Officer at GE Capital Bank and WebBank, respectively. Earlier in her career, Katrina served as the Audit Director for GE Capital, as well as a commissioned bank examiner with the FDIC. She holds an Executive MBA from the University of Utah and a BS in Accounting from Weber State University. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

March 21, 2023 02:30 PM Eastern Daylight Time

Video
Article thumbnail News Release

Colorado pet owners say yes, they want access to mid-level veterinary professionals and telehealth

Vet Care Coalition

Responding to increasing costs and unavailability due to the state’s significant veterinary workforce shortage, four out of five Colorado pet owners say they would not hesitate to have their animal seen by a newly-created mid-level veterinary professional associate, similar in function and oversight to a physician assistant (PA). These are among the findings of an independent survey of Colorado pet owners announced by the Vet Care Coalition (VetCareCoalition.com), an expanding alliance of animal welfare organizations, veterinarians and technicians, pet owners, ranchers and other experts working to establish workable solutions to the state’s costly veterinary workforce shortage. The Vet Care Coalition is pursuing legislation in Colorado’s statehouse to achieve three common-sense initiatives toward addressing the state’s veterinary shortage: 1. Establishing a path for creation of a mid-level veterinary professional associate (VPA), similar to a physician assistant (PA) in human medicine. A VPA will be a master’s degree-level professional working under the supervision of a veterinarian to provide care such as examining pets, diagnosing minor conditions, performing routine surgeries and leading healthcare teams. These professionals will generate practice revenue while increasing overall workforce capacity, helping to increase patient availability while lowering costs. 2. Codifying the availability of veterinary care through telehealth services, which are increasingly used in human medicine. More than half of the state’s pet owners surveyed said they would be comfortable using virtual veterinary care for their animals. 3. Expanding the role of registered veterinarian technician specialists (VTS), with additional training and credentialing. “Vet tech” specialists are often underutilized in veterinary practices because Colorado regulations unreasonably limit what they can legally do. Expanding the role of a VTS will increase veterinary care capacity across the state while helping encourage retention at a time when many are leaving the sector due to burn-out and lack of professional growth. Colorado’s veterinary shortage is well-documented In 2021, the U.S. Department of Agriculture identified 25 rural and urban Colorado counties as having “veterinary shortage situations” in food animal medicine – a situation that contributes to higher prices while putting food safety at risk. In addition, the Veterinary Care Accessibility Project (AccessToVetCare.org) gave Colorado a score of only 58 out of 100, noting that veterinary care is nearly inaccessible in much of the state. The shortage has had a negative impact on pet owners and their animals across the country – and could get much worse. A Mars Veterinary Health study found that without solutions put in place soon, the U.S. will have 15,000 fewer veterinarians than it needs by 2030, leaving some 75 million pets without any veterinary care at all. The Colorado survey, conducted in mid-January by Corona Insights research firm, asked 556 pet owners across the state how they have been impacted by the veterinary shortage and gauged their initial comfort level with being seen by a VPA or via telehealth services. The research found that high veterinary costs generate the greatest level of concern and dissatisfaction among pet owners, with almost 25 percent saying high costs made them decide against taking their animals in for necessary care over the last year. The U.S. Dept. of Labor Consumer Price Index shows that between 1997 and 2022, veterinarian services steadily rose at almost twice the rate of inflation. Through 2021 and 2022 alone, the nation’s veterinary shortage contributed to service prices increasing by more than 13 percent. More than a quarter of survey respondents also said they were significantly challenged in finding and making timely appointments with veterinarians in their area. Logical and urgent need for a mid-level veterinary professional “While the human medical profession has embraced physician assistants for more than 50 years, veterinary medicine inexplicably still has no such mid-level professional position,” said coalition spokesperson Dr. Apryl Steele, past president of the Colorado Veterinary Medical Association (CVMA) and current CEO of the Dumb Friends League. “Animals will suffer until we fill this glaring need,” said Dr. Steele, “while Colorado’s veterinary workforce will continue to be severely overworked and understaffed.” The American Medical Association (AMA) officially recognized physician assistants in 1971, with the first PA certification tests implemented by the National Board of Medical Examiners two years later. “The VPA would not replace a veterinarian or a veterinary technician,” said Dr. Steele. “Rather, it will enhance a practice while providing credentialed veterinary technicians with a career path toward greater responsibility and compensation.” In Colorado’s USDA-identified veterinary shortage areas, VPAs will be allowed to work under indirect supervision to help increase access to care for food and fiber animals. “It’s important to understand that fully utilizing veterinary technicians and creating a mid-level veterinary PA are complementary options for solving Colorado’s veterinarian workforce shortage crisis,” said Dr. Steele. “We absolutely need both.” About the Vet Care Coalition The Vet Care Coalition is an expanding alliance that includes animal welfare organizations, veterinarians and technicians, pet owners, ranchers and other experts with a common goal to find workable solutions to the state’s costly veterinary workforce shortage. Organizational coalition members supporting the legislation include the Animal Welfare Association of Colorado (AWAC), Colorado Voters for Animals, the Dumb Friends League (DFL), Thrive Pet Healthcare, Humane Society of the Pikes Peak Region (HSPPR), Roice-Hurst Humane Society, Virtual Veterinary Care Association, Animal Policy Group, WellHaven Pet Health, Larimer Humane Society, the American Society for the Prevention of Cruelty to Animals (ASPCA) and Mars Petcare. Individual supporters include four former presidents of the Colorado Veterinary Medical Association (CVMA), as well as a growing number of veterinarians, practice owners and animal welfare advocates across the nation. For more information and to support efforts to increase access to veterinary care across Colorado, please visit www.vetcarecoalition.com. Contact Details Vet Care Coalition Steven Silvers +1 720-402-8820 ssilvers@vetcarecoalition.com

March 21, 2023 08:50 AM Mountain Daylight Time

Article thumbnail News Release

Aqua Cultured Foods to Begin Consumer Tastings of Alt-Seafood

AquaCultured Foods

Food tech startup Aqua Cultured Foods today announced it will begin consumer tastings of its seafood alternatives at its Chicago facility in advance of launching publicly through chef partners and foodservice distributors. Aqua will offer participants Aqua tuna rolls, shrimp dumplings and scallop crudo, and solicit feedback. Tastings will be held in Aqua’s West Loop, Chicago headquarters beginning in early April. Aqua is developing a range of alt-seafood from proprietary mycoprotein fermentation processes. A unique strain of fungi transforms plant-based ingredients into “seafood” with a realistic taste, texture, and appearance that can be used as a one-to-one replacement for animal seafood. The company is also producing minced fillings for applications such as dumplings, ravioli, and sushi rolls. “Public tasting events will help us fine-tune products and learn what preparations are most successful, which will also help us create new menu items with chef and restaurant partners,” said Aqua CEO Anne Palermo. “Participants should arrive hungry and prepare to be wowed, because they’ve never had plant-based seafood that’s this delicious and this convincing.” Those interested in joining a tasting panel can sign up at https://www.eventbrite.com/e/aqua-customer-taste-panels-tickets-565576212677?aff=Newsletter. Aqua’s calamari, shrimp, scallops, and filets of tuna and whitefish are created using fermentation processes that do not use any animal inputs, genetic altering or modification. Unlike plant-based processed foods formulated with starches and protein isolates, Aqua’s alt-seafood retains its naturally occurring fiber, protein, and other micronutrients. The rising demand for seafood has led to depleted fish populations, ecosystem damage, plastic waste, and unintended “bycatch” of non-target species due to commercial fishing. As fish farming increases, so does habitat destruction, pollution and diseases in wild fish populations, and the industry’s reliance on antibiotics and wild-caught fish for feed. For images visit https://app.box.com/s/wfbrvgraf2ty2b7by5h6ahjsaqrd8zx3. About Aqua Cultured Foods Aqua Cultured Foods is an innovative food technology startup developing the world’s first whole-muscle cut seafood alternatives created through microbial fermentation. Its novel technology produces a sustainable, complete protein source using only a fraction of the resources required by traditional aquaculture. As the first to develop realistic alt-seafood with fermentation, Aqua Cultured Foods occupies a unique position in the burgeoning alt-seafood market, as well as within the fermentation industry. The company’s mission is to mitigate global challenges such as overfishing, climate change and feeding the world’s expanding population with delicious, nutrient-rich foods. For more information visit https://www.aquaculturedfoods.com. Contact Details Evolotus PR Gary Smith +1 818-783-0569 gary@evolotuspr.com Company Website https://www.aquaculturedfoods.com

March 21, 2023 09:30 AM Eastern Daylight Time

12345 ... 189